Quality-of-life methodology in hormone receptor –positive advanced breast cancer: current tools and perspectives for the future
There is currently no cure for advanced breast cancer [1 –3]. The primary goals of patient care are to prolong survival, minimize disease symptoms, and maximize health-related quality of life (HRQOL) [2]. Given the severity of the disease and potential toxicity associated with treatment, assessment of patient-reported HRQOL is gaining importance as a tr eatment goal in clinical trials of cancer drugs and is accepted by the US Food and Drug Administration and European Medicines Agency as an outcome to be considered in addition to efficacy endpoints during the drug evaluation process [4–7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 17, 2021 Category: Cancer & Oncology Authors: Fatima Cardoso, David Cella, Galina Velikova, Victoria Harmer, Eva Schumacher-Wulf, Julie Rihani, Ana Casas, Nadia Harbeck Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 13, 2021 Category: Cancer & Oncology Source Type: research
SELNET Clinical practice guidelines for soft tissue sarcoma and GIST
Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing more than 80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma. Bone sarcomas are covered in a different paper. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 13, 2021 Category: Cancer & Oncology Authors: Blay JY, Hindi N, Bollard J, Aguiar Jr S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-S ánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Source Type: research
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: current evidence, advances, and future perspectives
With over 935,000 deaths estimated to occur annually, colorectal cancer (CRC) is the second leading cause of cancer-related mortality [1]. Each year, ∼1.9 million cases of CRC occur worldwide, including ∼322,000 cases in North America and Western Europe [1], with metastatic disease developing in nearly 40% [2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 10, 2021 Category: Cancer & Oncology Authors: Gunnar Folprecht, Erika Martinelli, Thibault Mazard, Dominik P. Modest, Akihito Tsuji, Regina Esser, Chiara Cremolini, Alfredo Falcone Source Type: research
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – a review
With 570,000 cases and 311,000 deaths yearly, cervical cancer currently ranks fourth in cancer incidence and mortality [1]. Radical hysterectomy with pelvic lymphadenectomy is the standard treatment for clinically visible early-stage disease and chemoradiotherapy for more advanced stages. Upon intraoperative discovery of lymph node metastasis, the gynaecologist may pursue one of two treatment strategies. Abandonment of radical hysterectomy followed by primary (chemo)radiotherapy (PRT), is currently recommended by international guidelines [2,3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - November 2, 2021 Category: Cancer & Oncology Authors: Hans H.B. Wenzel, Ester P. Olthof, Ruud L.M. Bekkers, Ingrid A. Boere, Valery E.P.P. Lemmens, Hans W. Nijman, Lukas J.A. Stalpers, Maaike A. van der Aa, Jacobus van der Velden, Constantijne H. Mom Source Type: research
KRAS Inhibitors – yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal, and pancreatic cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations [1]. The KRAS protein is a GTPase that transmits intracellular signals upon binding to GTP [2 –3]. Under physiologic conditions, this system is maintained by guanine nucleotide exchange factors, favoring the GDP-bound inactive form. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 20, 2021 Category: Cancer & Oncology Authors: Misako Nagasaka, Bindu Potugari, Alexis Nguyen, Ammar Sukari, Asfar S Azmi, Sai-Hong Ignatius Ou Source Type: research
KRAS Inhibitors- Yes But What Next? Direct targeting of KRAS- Vaccines, Adoptive T Cell Therapy and Beyond
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal, and pancreatic cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations [1]. The KRAS protein is a GTPase that transmits intracellular signals upon binding to GTP [2 –3]. Under physiologic conditions, this system is maintained by guanine nucleotide exchange factors, favoring the GDP-bound inactive form. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 20, 2021 Category: Cancer & Oncology Authors: Misako Nagasaka, Bindu Potugari, Alexis Nguyen, Ammar Sukari, Asfar S Azmi, Sai-Hong Ignatius Ou Source Type: research
Genomic Sequencing to Inform Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies
Pancreatic cancer is projected to overtake colorectal cancer to become the second most frequent cause of cancer death by 2030, with approximately 46,000 people in the US dying annually[1]. Pancreatic cancer is uniquely challenging for several reasons. In contrast to other cancers, screening has limited utility outside of rare genetic conditions[2], most cancers present at an advanced and incurable stage[3], and the latest advances in cancer therapy such as immunotherapy have not provided benefit[4,5] in unselected pancreatic cancer so far. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 20, 2021 Category: Cancer & Oncology Authors: Nicholas Meti, Deirdre Kelly, Michael J. Allen, Ashley Lanys, Rouhi Fazelzad, Ravi Ramjeesingh, George Zogopoulos, Faiyaz Notta, Jennifer J. Knox, Eitan Amir, Steven Gallinger, Grainne O'Kane, Robert C. Grant Source Type: research
Major breakthroughs in lung cancer adjuvant treatment: looking beyond the horizon
Approximately 30% of non-small cell lung cancer (NSCLC) patients present a resectable disease at the time of diagnosis [1] and this proportion will hopefully increase in the near future through the implementation of screening programs worldwide [2]. The prognosis of surgically resected NSCLC patients, is mainly ascribed to the pathological TNM staging, with 5-year survival rate dropping from 90% (stage IA) to 40% (stage IIIA) [3]. In this heterogeneous scenario, the optimal management of early stage NSCLC patients has historically represented a difficult and appealing challenge for medical oncologists dealing with thoracic...
Source: Cancer Treatment Reviews - October 18, 2021 Category: Cancer & Oncology Authors: Francesco Passiglia, Valentina Bertaglia, Maria Lucia Reale, Marco Donatello Delcuratolo, Fabrizio Tabb ò, Emanuela Olmetto, Enrica Capelletto, Paolo Bironzo, Silvia Novello Source Type: research
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors
Immune-checkpoint inhibitors (ICIs) including Programmed Death-1 (PD-1) or Programmed Death Ligand-1 (PD-L1) inhibitors determined a significant improvement in the treatment of several cancer types [1,2]. However, a considerable proportion of patients does not benefit from them [3,4]. Combining PD-1 or PD-L1 inhibitors with other therapeutic partners - including a second immunotherapeutic agent, targeted agents, chemotherapy or radiotherapy - has been increasingly pursued over the last years [5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 17, 2021 Category: Cancer & Oncology Authors: F. Martorana, I. Colombo, G. Treglia, S. Gillessen, A. Stathis Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 14, 2021 Category: Cancer & Oncology Source Type: research
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
Neuroendocrine neoplasms (NEN) of thegastroenteropancreatic(GEP) tract, hereby referred to as GEP-NENs, are aheterogeneousgroup oftumours originating from neuroendocrine cells of the gastrointestinal tract.[1] Neuroendocrine neoplasms comprise both well-differentiated neuroendocrine tumours (NET) and poorly-differentiated neuroendocrine carcinomas (NEC), which differ significantly in clinical behaviour.[2] Although considered a rare group of cancers, the incidence ofGEP-NENs has increased in all primary sites over the last four decades, with an overall incidence of 5.25 per 100,000 per year. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 10, 2021 Category: Cancer & Oncology Authors: Rachel Broadbent, Roseanna Wheatley, Sabrina Stajer, Timothy Jacobs, Angela Lamarca, Richard A Hubner, Juan W Valle, Eitan Amir, Mair éad G McNamara Source Type: research
De-escalation of axillary irradiation for early breast cancer – has the time come?
Decades of progress in early breast cancer (BC) treatment, in particular advances in early detection and tumor-biology-driven systemic therapy have resulted in improvements in both local/distant control and overall survival (OS) [1]. Resultant improved disease control together with the morbidity associated with locoregional treatments have led to locoregional treatment (surgery and radiation) de-escalation attempts, aiming to decrease treatment-related sequelae and – as a result – improve patients’ quality-of-life. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 7, 2021 Category: Cancer & Oncology Authors: El żbieta Senkus, Maria Joao Cardoso, Orit Kaidar-Person, Aleksandra Łacko, Icro Meattini, Philip Poortmans Source Type: research
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
Ovarian cancer (OC) is the major cause of gynecological cancer-related deaths in Western countries[1]. Its relative low incidence and the absence of screening programs, represent major limitations to early disease detection[2]. As a result, OC is usually diagnosed at late stage with unfavorable impact on the outcome. Cytoreductive surgery, aimed to remove all the macroscopic implants from the abdomen and the pelvis, represents the only curative treatment option and is the therapeutic mainstay in early and advanced OC. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 29, 2021 Category: Cancer & Oncology Authors: M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata Source Type: research
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, even if its incidence has decreased over time, mainly because of prevention and treatment of Helicobacter pylori infection[1]. Contrarily, the incidence of gastro-esophageal junction (GEJ) adenocarcinomas has increased, attributable to smoking and elevated body mass index (BMI) [2]. Much progress has been made in the management of advanced G/GEJ adenocarcinomas: the identification of molecular sub-groups benefiting from specific therapies (HER2 positive tumors, MSI/dMMR and EBV positive tumors, FGFR amplified tumors, etc)[3 –6], the introduc...
Source: Cancer Treatment Reviews - September 20, 2021 Category: Cancer & Oncology Authors: C. de la Fouchardiere, L. Decoster, E. Samalin, C. Terret, C. Kenis, J.P. Droz, C. Coutzac, E. Smyth Source Type: research
